(NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Re ...

Illumina (ILMN) could be a solid addition to your portfolio ... which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing ...

Illumina (NASDAQ:ILMN – Get Free Report ... s price target indicates a potential upside of 25.32% from the stock’s current price. Other equities research analysts have also recently issued ...

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during ...

While the recent gains have been impressive, the company’s share price is actually recovering after a sharp selloff. Through five years, ILMN stock is down 46% at current levels. Improving ...

Shares of Illumina (NASDAQ:ILMN) fell 6% post-market Monday after the company lowered its fiscal 2024 revenue guidance. The DNA sequencing company reported Q3 adjusted EPS of $1.14, which beat the ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Illumina fair value estimate is US$152 Illumina's US$155 share... The headline numbers for Illumina (ILMN) give insight into how the company ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Illumina fair value estimate is US$152 Illumina's US$155 share... Despite a slight revenue decline, Illumina Inc (ILMN) focuses on expanding ...

We expect the latest development to positively boost market sentiment toward ILMN stock. Illumina currently has a market capitalization of $20.74 billion. The company’s earnings in 2024 are ...

20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global ...